title: Treatment outcome and risk factors for visual loss in Cytomegalovirus endotheliitis.
abstract: BACKGROUND
  To determine treatment outcome and risk factors for visual loss in Cytomegalovirus (CMV) endotheliitis.
  
  
  METHODS
  Retrospective case-note review of all CMV positive endotheliitis patients seen at the Singapore National Eye Center, for demographics, visual acuity (VA), extent of corneal edema, anterior chamber (AC) activity, ocular history, glaucomatous optic neuropathy (GON), and ganciclovir therapy. Outcome measures were VA, corneal edema, and AC activity.
  
  
  RESULTS
  Median age at diagnosis of the 19 patients (21 eyes) was 57 years. Median duration of follow up was 37 months. Sixteen eyes received systemic ganciclovir, and four eyes received ganciclovir gel. The AC inflammation resolved in 19 eyes. The corneal edema resolved in eight eyes, but persisted in 12 eyes. One patient resolved spontaneously. Pre-treatment corneal edema exceeding 75%, older age, GON, and previous corneal graft were risk factors for persistent corneal edema post treatment (P = < 0.001, 0.001, 0.02 and 0.02 respectively, Fisher's exact test), and VA worse than 6/60.
  
  
  CONCLUSIONS
  Anterior chamber inflammation resolves with ganciclovir therapy, but severe pre-treatment corneal edema, older age, previous corneal graft, and GON are associated with a poor visual outcome.
authors: Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore, 168751, Singapore. chee.soon.phaik@snec.com.sg
authors: Soon-Phaik
authors: SP
authors: Chee
authors: Aliza
authors: A
authors: Jap
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use; D001082:Aqueous Humor / Q000821:virology; D001766:Blindness / Q000453:epidemiology*; D003587:Cytomegalovirus / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification*; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000821:virology; D004279:DNA, Viral / Q000032:analysis; D004728:Endothelium, Corneal / Q000821:virology*; D015828:Eye Infections, Viral / Q000188:drug therapy* / Q000821:virology; D005260:Female; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D015483:HIV Antibodies / Q000097:blood; D006801:Humans; D007262:Infusions, Intravenous; D007634:Keratitis / Q000188:drug therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D000077562:Valganciclovir; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000914:Antibodies, Viral; D000998:Antiviral Agents; D004279:DNA, Viral; D015483:HIV Antibodies; D000077562:Valganciclovir; D015774:Ganciclovir